AJA 001
Alternative Names: AJA-001Latest Information Update: 07 Aug 2024
At a glance
- Originator AJNA Australia
- Class Behavioural disorder therapies; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pervasive child development disorders
Most Recent Events
- 15 May 2024 AJNA Australia completes a phase-I (In volunteers) in Australia (PO), (NCT06019065)
- 13 Dec 2023 Phase-I clinical trials in Pervasive child development disorders (In volunteers) in Australia (PO) before December 2023
- 13 Dec 2023 AJNA Australia plans to submit an IND application with the US FDA for a phase II trial